BMC Health Services Research (Dec 2019)

Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis

  • Kerry Mansell,
  • Hishaam Bhimji,
  • Dean Eurich,
  • Holly Mansell

DOI
https://doi.org/10.1186/s12913-019-4829-z
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 3

Abstract

Read online

In the original publication of this article [1], there is a mistake in the Fig. 2a, 2b, and 2c.